The 2017 IO Summit Emerging Investigator Initiative

The IO Summit 2017, being held August 28-September 1, will feature a new initiative wherein a select number of presentations will be given by rising stars from the field of immune-oncology. The goal of this initiative is to not only showcase the future of the field, but also to provide our delegates with cutting-edge research that they won’t see elsewhere.

Emerging Investigator Presentations Include:

Immunomodulatory Therapeutic Antibodies for Cancer

Immunomodulatory Antibodies – Potentiation by Fc Receptor Engagement

Rony Dahan, Ph.D., Principal Investigator, Immunology, Weizmann Institute of Science, Israel

The Role of Metabolism in Immune Response in Tumors: Merging the Past and the Present of Tumor Microenvironment

Allison S. Betof, M.D., Ph.D., Medical Oncology Fellow, Memorial Sloan Kettering Cancer Center

PI3Kgamma Is a Molecular Switch that Controls Immune Suppression

Megan M. Kaneda, Ph.D., Assistant Project Scientist, University of California, San Diego

Please click here for the full agenda

Emerging Techniques in Synthetic Biology

Hacking Immune Cells with Synthetic Notch Receptors to Expand Their Therapeutic Potential

Kole T. Roybal, Ph.D., Assistant Professor, Microbiology, Immunology, University of California San Francisco

Synthetic Biology Approaches for Engineering Platelets as Delivery Systems for Treating Disease

Tara L. Deans, Ph.D., Assistant Professor, Bioengineering, University of Utah

Please click here for the full agenda

Preclinical and Translational Immuno-Oncology

Using Radiation to Elicit in situ Tumor Vaccination

Zachary S. Morris, M.D., Ph.D., Assistant Professor, Human Oncology, University of Wisconsin School of Medicine and Public Health

The Role of Batf-3 DC in the T Cell-Inflamed Tumor Microenvironment

Stefani Spranger, Ph.D., Assistant Professor, Biology, MIT

Vaccine Therapy for Primary and Secondary Breast Cancer Prevention

Sasha Stanton, M.D., Ph.D., Acting Instructor, Breast Oncology, University of Washington Tumor Vaccine Group

Please click here for the full agenda

Emerging Immuno-Oncology Targets

Targeting IDO1 to Enhance Cancer Immunotherapy: Not So Simple After All

Derek A. Wainwright, Ph.D., Assistant Professor, Departments of Neurological Surgery, Microbiology-Immunology, and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine

Development of TGFβ Inhibitors for Immune-Oncology

Rikke Holmgaard, Ph.D., Senior Research Scientist, Eli Lilly

Dual Targeting Bispecific Antibodies Selectively Block Innate Immune Checkpoint Receptor CD47 on Tumor Cells

Stefano Majocchi, Ph.D., Research Scientist, Novimmune SA

Predicting the Efficacy and Safety Profile of ImmTAC™ Molecules: The Preclinical Challenge

Martina Canestraro, Ph.D., Senior Scientist, Preclinical Biology, Immunocore, Ltd.

Please click here for the full agenda

Oncolytic Virus Immunotherapy

Development of OV Immunotherapy Using a Novel Preclinical GBM Model

Hiroshi Nakashima, Ph.D., Instructor, Neuroscience, Brigham and Women’s Hospital

Oncolytic Virus-Induced Rad51 Degradation: Synergy with Poly(Adp-Ribose) Polymerase Inhibitors in Treating Glioblastoma

Jianfang Ning, Ph.D., Instructor, Neurosurgery, Massachusetts General Hospital, Harvard Medical School

Please click here for the full agenda

Adoptive T Cell Therapy

PET-Imaging of Chimeric Antigen Receptor T Cells

David Huss, Ph.D., Senior Scientist, CAR T Cell Team Lead, Juno Therapeutics

Please click here for the full agenda

Quantitative Immune Profiling and Immune Monitoring

Antigen-Presenting Tumor B Cells Impact the Phenotype of CD4 Tumor Infiltrating T Cells in Lung Cancer Patients

Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh

Quantifying Non-Self in Cancer

Benjamin Greenbaum, Ph.D., Assistant Professor, Medicine, Oncological Sciences, and Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Please click here for the full agenda

Biomarkers for Immuno-Oncology

Understanding the Heterogeneity and Dynamics of Responses to Checkpoint Blockade in Melanoma

Alexandre Reuben, Ph.D., Postdoctoral Fellow, Surgical Oncology, The University of Texas MD Anderson Cancer Center

Biomarkers of Response/Progression in RCC Patients Receiving PD-1/PD-L1 Inhibitors

Aly-Khan Lalani, M.D., Genitourinary Oncology Fellow, Dana-Farber Cancer Center

Please click here for the full agenda

Advances in Vaccine Technologies

A Systems Approach to Develop HIV Vaccines

Jishnu Das, Ph.D., Postdoctoral Associate, Lauffenburger Lab, Biological Engineering, MIT & Alter Lab, Ragon Institute of MGH, MIT & Harvard 

Please click here for the full agenda

Vaccine Adjuvants

Driving Humoral Responses against HIV Envelope via Multivalent Display of Env Trimers on Synthetic Liposomes

Talar Tokatlian, Ph.D., Postdoctoral Research Associate, Irvine Lab, Massachusetts Institute of Technology

Please click here for the full agenda